Kimberly Belzer

Learn More
BACKGROUND Pemetrexed has emerged as one of the most active agents for the treatment of patients with advanced non-small cell lung cancer (NSCLC). We conducted a phase II study to assess the efficacy and feasibility of integrating pemetrexed in a concurrent therapy plan for patients with stage III NSCLC. METHODS Patients with stage III NSCLC with(More)
PURPOSE This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received gemcitabine 3000 mg/m(2) intravenously over 30 minutes and paclitaxel 150 mg/m(2) over 3 hours every 2 weeks.(More)
7094 Background: Chemotherapy response rates in platinum refractory NSCLC are very limited. Geftinib (Iressa), an Epidermal Growth Factor Receptor (EGFR) inhibitor, demonstrates a 12%-18% response rate in previously treated NSCLC. Cyclooxygenase-2 (COX-2) is overexpressed in 50-70% of NSCLC and it promotes tumor growth through the production of(More)
OBJECTIVE Although combined modality therapy appears to be superior to radiotherapy alone for the treatment of locally advanced non-small cell lung cancer (NSCLC), the optimal treatment regimen has not been determined. We designed this trial to determine the maximal tolerated doses (MTD) of continuous intravenous infusion (CI) cisplatin and etoposide that(More)
  • 1